Literature DB >> 18184715

The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.

April J Schumacher1, Guylaine Haché, Donna A Macduff, William L Brown, Reuben S Harris.   

Abstract

Human APOBEC3G and several other APOBEC3 proteins have been shown to inhibit the replication of a variety of retrotransposons and retroviruses. All of these enzymes can deaminate cytosines within single-strand DNA, but the overall importance of this conserved activity in retroelement restriction has been questioned by reports of deaminase-independent mechanisms. Here, three distinct retroelements, a yeast retrotransposon, Ty1, a murine endogenous retrovirus, MusD, and a lentivirus, human immunodeficiency virus type 1 (HIV-1), were used to evaluate the relative contributions of deaminase-dependent and -independent mechanisms. Although human APOBEC3G can restrict the replication of all three of these retroelements, APOBEC3G lacking the catalytic glutamate (E259Q) was clearly defective. This phenotype was particularly clear in experiments with low levels of APOBEC3G expression. In contrast, purposeful overexpression of APOBEC3G-E259Q was able to cause modest to severe reductions in the replication of Ty1, MusD, and HIV-1(DeltaVif). The importance of these observations was highlighted by data showing that CEM-SS T-cell lines expressing near-physiologic levels of APOBEC3G-E259Q failed to inhibit the replication of HIV-1(DeltaVif), whereas similar levels of wild-type APOBEC3G fully suppressed virus infectivity. Despite the requirement for DNA deamination, uracil DNA glycosylase did not modulate APOBEC3G-dependent restriction of Ty1 or HIV-1(DeltaVif), further supporting prior studies indicating that the major uracil excision repair system of cells is not involved. In conclusion, the absolute requirement for the catalytic glutamate of APOBEC3G in Ty1, MusD, and HIV-1 restriction strongly indicates that DNA cytosine deamination is an essential part of the mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184715      PMCID: PMC2259018          DOI: 10.1128/JVI.02391-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells.

Authors:  R S Harris; D S Croom-Carter; A B Rickinson; M S Neuberger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G.

Authors:  Kuan-Ming Chen; Natalia Martemyanova; Yongjian Lu; Keisuke Shindo; Hiroshi Matsuo; Reuben S Harris
Journal:  FEBS Lett       Date:  2007-09-07       Impact factor: 4.124

Review 5.  Uracil in DNA--occurrence, consequences and repair.

Authors:  Hans E Krokan; Finn Drabløs; Geir Slupphaug
Journal:  Oncogene       Date:  2002-12-16       Impact factor: 9.867

6.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

7.  APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Authors:  Mark T Liddament; William L Brown; April J Schumacher; Reuben S Harris
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

8.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

9.  Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase.

Authors:  Javier Di Noia; Michael S Neuberger
Journal:  Nature       Date:  2002-07-31       Impact factor: 49.962

10.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

View more
  115 in total

1.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.

Authors:  John S Albin; Rebecca S LaRue; Jessalyn A Weaver; William L Brown; Keisuke Shindo; Elena Harjes; Hiroshi Matsuo; Reuben S Harris
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

4.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

5.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

6.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

7.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

8.  Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.

Authors:  Guylaine Haché; Truus E M Abbink; Ben Berkhout; Reuben S Harris
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

10.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.